Lung Cancer: Our Research

The work of MCCC’s lung cancer collaborative (Victorian Lung Cancer Initiative) is a leading Victorian program which has resulted in:

  • The Victorian Lung Cancer Registry clinical patient data repository to inform quality clinical practice and direct lung cancer research
  • A lung cancer molecular pathology platform to provide access for lung cancer patients to molecular diagnostic technologies enabling referral to the most appropriate clinical trials
  • Preclinical research investigating new strategies to prevent chemoresistance in the treatment of small cell lung cancer
  • Preclinical research investigating the role of stem cell biomarkers to reliably predict relapse in early-stage non-small cell lung cancer
  • Best practice guidelines for General Practitioners for the for the assessment and management of lung cancer
  • A bank of lung cancer biopsies for research purposes.


Dr Muhammad Alamgeer , Medical Oncologist and Research Fellow at Monash Health, is evaluating the potential role of two putative cancer stem cell biomarkers to reliably predict relapse in early stage non-small cell lung cancer (NSCLC), after surgery. Published in December 2013, Dr Alamgeer’s research has determined that the co-expression of ALDH1A1 and CD133, is strongly associated with poor survival in early-stage NSCLC following surgical resection. These data are consistent with the hypothesis that expression of stem cell markers correlates with recurrence as an indirect measure of self-renewal capacity. (Alamgeer M1, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M, Conron M, Wright G, Watkins DN. The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax. 2013 Dec;68(12):1095-104. doi: 10.1136/thoraxjnl-2012-203021. Epub 2013 Jul 22).